secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aridis Pharmaceuticals, Inc. (—)
CIK:        0001614067
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001493152-23-027356
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aridis Pharmaceuticals CFO Fred Kurland resigns effective Aug 4, 2023 due to retirement
--------------------------------------------------------------------------------

- CFO Fred Kurland resigned on August 4, 2023, citing retirement.
- Kurland will serve as senior financial consultant to the Company.
- VP of Finance Tamara Allen continues to lead all financial accounting and reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223027356/0001493152-23-027356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223027356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer